Recent cases involve charges and judgments related to COVID-19 add-on tests, genetic testing fraud, and kickbacks.
Proposed rule would require businesses to undergo even more stringent review to secure regulatory approval for such deals.
The recent 8-1 decision expands the DOJ’s power to request such cases be thrown out.
A recent SCOTUS ruling on a healthcare fraud case could help defend labs against baseless whistleblower cases.
Ruling could spell good news for labs and other healthcare providers targeted by whistleblowers in False Claims Act qui tam lawsuits.